Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

REVASC-PAD: ESERCIZIO VASCOLARE LIMITATO per la Malattia Arteriosa Periferica - Uno Studio di Fattibilità presso il Centro Medico dell'Università del Tennessee (REVASC-PAD)

The purpose of this study is to evaluate the effects of Blood Flow Restriction (BFR) training on walking function, health-related quality of life, and safety among adults with Peripheral Arterial Disease (PAD).

The main aims of the study are:

  1. Evaluate change in walking function among patients with PAD undergoing BFR training. The investigators will assess change in Six-Minute Walk Test (6MWT) distance from baseline to post-intervention and 3-month follow-up to compare functional improvements between the BFR group and the two control groups
  2. Assess changes in health-related quality of life among patients with PAD undergoing BFR training. The investigators will use the EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale to evaluate quality-of-life changes from baseline to post-intervention and 3-month follow-up across all study arms
  3. Evaluate the safety and feasibility of a supervised BFR training program for patients with PAD. The investigators will compare adverse event (AE) and serious adverse event (SAE) rates across study arms, while also monitoring sessional ratings of perceived exertion (RPE), dyspnea, and claudication pain as indicators of symptom response and exercise tolerance. Feasibility will be assessed through enrollment success, intervention adherence, and retention rates across groups

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

81

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Tiffany Johnson, Study Coordinator
  • Numero di telefono: +1865-305-4682
  • Email: thjohnson@utmck.edu

Luoghi di studio

    • Tennessee
      • Knoxville, Tennessee, Stati Uniti, 37920
        • Reclutamento
        • University of Tennessee Medical Center
        • Investigatore principale:
          • Morgan Randall, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. 18 years of age or older
  2. Diagnosed peripheral arterial disease with stable claudication (symptomatic presentation unchanged for 6 months)
  3. Ankle-brachial index (ABI) between 0.4 and 0.9.
  4. Eligible referral to cardiovascular or pulmonary rehabilitation
  5. Prior revascularization permitted if symptoms are stable and other criteria are met

Exclusion Criteria:

  1. Recent change in resting ECG suggesting significant ischemia, recent myocardial infarction (within 2 weeks), or another acute cardiac event
  2. Unstable angina
  3. Uncontrolled cardiac arrhythmias
  4. Symptomatic severe aortic stenosis or other significant valvular disease
  5. Decompensated symptomatic heart failure
  6. Acute pulmonary embolism or infarction
  7. Acute noncardiac disorder likely to interfere with or be worsened by exercise (e.g., infection, thyrotoxicosis)
  8. Acute myocarditis or pericarditis
  9. Acute thrombophlebitis
  10. Physical disability precluding safe or adequate exercise performance
  11. Significant electrolyte abnormalities
  12. Clinically significant tachyarrhythmias or bradyarrhythmias
  13. High-degree atrioventricular block
  14. Atrial fibrillation with uncontrolled ventricular response
  15. Hypertrophic obstructive cardiomyopathy with resting left ventricular outflow gradient of >25 mmHg
  16. Known active aortic dissection
  17. Severe resting arterial hypertension (SBP>200mmHg or DBP >110 mmHg)
  18. Mental impairment preventing cooperation with study procedures
  19. Current pregnancy
  20. Moderate to severe peripheral neuropathy
  21. Open wounds or compromised skin near BFR cuff site
  22. Active DVT or thromboembolic event within the past year

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Blood Flow Restriction (BFR) Training

Participants perform supervised lower-body resistance training using pneumatic cuffs (Smart Cuff Pro or equivalent) applied to the proximal thighs. Cuffs are inflated to 60-80% of the participant's measured arterial occlusion pressure (AOP). Pressure is increased at Weeks 5 and 9 based on tolerance. Cuff inflation will not exceed 80% of limb occlusion pressure. Cuffs will be immediately deflated if participants' vitals suggest poor tolerance.

All BFR resistance sessions will include two standardized lower-extremity exercises: seated calf raises and standing calf raises. Each session will follow this protocol:

  1. 1 set of 30 repetitions, followed by 3 sets of 15 repetitions
  2. 30 seconds rest between sets, with the cuff remaining inflated
  3. Load set at 20-35% of 1RM
  4. Cuff deflated immediately after the fourth set or after 6 continuous minutes of inflation, whichever comes first
Comparatore attivo: Low-Load Traditional Resistance Training (LL-RT)

Participants perform the same two calf exercises (seated and standing calf raises) without BFR cuffs. If participants demonstrate the ability to complete all prescribed repetitions without undue strain, planned load progressions of approximately 5-10% 1RM will be introduced at Weeks 5 and 9. Repetitions and sets will remain fixed to match the BFR protocol.

Two resistance exercises (seated and standing calf raises) using the same repetition structure

  1. 1 set of 30 repetitions, followed by 3 sets of 15 repetitions
  2. Load set at 20-35% of 1RM
  3. 30 seconds rest between sets
  4. No BFR cuffs will be used
Comparatore attivo: High-Load Traditional Resistance Training (HL-RT)

Participants in this group will perform seated and standing calf raises following a more conventional strength training model. Similar to the other groups, if participants can complete their prescribed workload without excessive strain, two planned load progressions (5-10% 1RM) will be applied at Weeks 5 and 9. Repetitions and sets will remain fixed to preserve consistency in training structure across groups. This group serves as a benchmark for conventional resistance training in clinical and musculoskeletal rehabilitation populations.

Each session includes:

  1. 3 sets of 8-12 repetitions
  2. Load set at 60-70% of 1RM
  3. Rest periods of 60-90 seconds between sets
  4. No BFR cuffs will be used

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Walking Function
Lasso di tempo: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in walking distance measured by the Six-Minute Walk Test (6MWT) from baseline to end of intervention and 3-month follow-up visit.

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
Quality of Life (QoL) (1)
Lasso di tempo: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in health-related quality of life as assessed by EuroQol 5-Dimension 5-Level (EQ-5D-5L) from baseline to post-intervention and 3-month follow-up

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
Quality of Life (QoL) (2)
Lasso di tempo: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in depressive symptoms as assessed by Patient Health Questionnaire-9 (PHQ-9) from baseline to post-intervention and 3-month follow-up

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
Quality of Life (QoL) (3)
Lasso di tempo: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in self-reported walking function and symptom burden assessed by using REVASC-PAD Walking Questionnaire from baseline to post-intervention and 3-month follow-up

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Claudication Onset Time (COT) during 6MWT
Lasso di tempo: Baseline, post-intervention (8 to 12 weeks), and 3 months post-intervention

Time to onset of claudication symptoms during 6MWT at baseline, post-intervention, and 3-month follow-up

Baseline, post-intervention (8 to 12 weeks), and 3 months post-intervention
Ratings of Perceived Exertion (RPE), Dyspnea, and Claudication Pain
Lasso di tempo: Multiple assessments from Visit 2 through end of intervention (approximately 8 to 12 weeks)

Session-based self-reported symptom ratings collected at each supervised exercise session from Visit 2 to end of intervention (approximately 8 to 12 weeks). These ratings assess exercise tolerance and symptom burden during blood flow restriction training.

Multiple assessments from Visit 2 through end of intervention (approximately 8 to 12 weeks)
Adverse Event (AE) and Serious Adverse Event (SAE) Rates
Lasso di tempo: Baseline to 3-month follow-up

Number and rate of adverse events and serious adverse events occurring during the study period.

Baseline to 3-month follow-up
Enrollment, Retention, and Adherence Rates
Lasso di tempo: Baseline to 3-month follow-up

Rates of successful enrollment, participant retention at post-intervention and 3-month follow-up, and adherence to prescribed exercise sessions

Baseline to 3-month follow-up

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

27 aprile 2026

Completamento primario (Stimato)

27 aprile 2027

Completamento dello studio (Stimato)

27 aprile 2027

Date di iscrizione allo studio

Primo inviato

24 ottobre 2025

Primo inviato che soddisfa i criteri di controllo qualità

28 ottobre 2025

Primo Inserito (Effettivo)

31 ottobre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

4 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 5460
  • Institutional Review Board (Altro identificatore: The University of Tennessee Health Science Center)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi